Talking Biotech: Pet dogs with genetic diseases testing ground for gene therapy

The promises of gene therapy have been slow to reach the public for many reasons. Technologies conceived in the 1980s had a substantial regulatory and proof-of-concept road ahead of them, leading to slow development and deployment.

One of the major issues is that these therapies were designed for humans, where ethics concerns and regulation are a challenge to navigate. However, it is possible to demonstrate efficacy in animals. Emily Mullin is the Associate Editor at MIT Technology Review. She recently covered the application of gene therapy to animals, and now describes its application in veterinary capacities where regulation is much lower than in human therapy.

Related article:  Gene doping in sports entails challenges and dangers but may not be so dopey

Follow Emily on Twitter: @emilylmullin

Read her work at MIT Technology Review

Follow Talking Biotech on Twitter @TalkingBiotech

Follow Kevin Folta on Twitter @kevinfolta | Facebook: | Lab website: | All funding:

Stitcher | iTunes | Player FM | TuneIn


News on human & agricultural genetics and biotechnology delivered to your inbox.

Send this to a friend